Hormonal
Higher baseline levels of inflammation (indicated by insulin, IL-6, adipose tissue inflammation, cortisol, and leptin) are associated with a worse weight loss response to lifestyle modification therapy.
If you have high insulin or inflammation, standard diet and exercise advice may be less effective for you. This doesn't mean you can't lose weight, but it may require more targeted approaches, such as specific dietary changes (e.g., low-carbohydrate vs. low-fat) or medications that address these specific hormonal issues. Consult a provider to check these markers.
Combined, these studies suggest that higher levels of inflammation (as expressed by such factors as adipose tissue inflammation, cortisol, adiponectin, and leptin) appear to be associated with a worse weight loss response to LMT.
Why this rating
Based on multiple prospective trials and cohort studies cited in the review.
Source
Precision medicine in adult and pediatric obesity: a clinical perspective
Eric M. Bomberg et al. · Therapeutic Advances in Endocrinology and Metabolism · 2019
DOI 10.1177/2042018819863022
More from this paper
- Early weight loss (e.g., >= 5% at 3-4 months) is a strong predictor of sustained long-term weight loss across various obesity interventions, including pharmacotherapy and lifestyle modification.Strong
- Person-specific characteristics (genetic, hormonal, psychosocial, and behavioral) significantly predict individual variability in weight loss response to obesity interventions, making precision medicine strategies potentially more effective than broad application of treatments.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →